Hutchison China MediTech Ltd ("Chi-Med"): Focused on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. Chi-Med has a portfolio of 8 drugs in clinical development from own discovery engine in its Innovation platform and a cash generating Commercial platform with 2,500+ sales reps. Launched fruquintinib, partnered with Eil Lilly, in late stage colorectal cancer in China in November 2018. Global collaboration with AstraZeneca in two registration enabling studies with savolitinib in Tagrisso refractory lung cancer that is MET+ and EGFRm+ (global) and MET Exon 14 deletion NSCLC (China). Potential to start two registration programs globally in 2020.
Sector/industry:
Healthcare/Drug Manufacturers
Characteristics:
Based in...
ROW
Clinical Stage
Marketed, Phase III, Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune, Immunotherapy, Oncology
Finance
Profitable, Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Website:
Address:
230 Park Ave
10th Fl
New York, NY 10169
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.